DISTRICT OF COLUMBIA: The Food and Drug Administration (FDA) announced that products which contain cannabidiol (CBD) cannot be sold as dietary supplements. The agency, however, left open the possibility that would it consider contrary evidence.
The FDA’s website provides questions and answers pertaining its policies on marijuana. The way the questions were written provides avenues for addressing the agency’s view and for showing that cannabis-derived products that contain cannabidiol can be sold as a dietary supplement.
The FDA said that a substance authorized as a new drug for which clinical investigations had begun cannot be introduced in a dietary supplement. Although federal law carves out an exception for substances already in a dietary supplement prior to authorization of the investigational new drug (IND), the FDA determined the exception did not apply to CBD.